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Abstract
Rhabdomyolysis is a syndrome caused by injury to skeletal muscle that usually leads to acute 
kidney injury (AKI). Rhabdomyolysis has been linked to different conditions, including severe 
trauma and intense physical exercise. Myoglobin-induced renal toxicity plays a key role in 
rhabdomyolysis-associated kidney damage by increasing oxidative stress, inflammation, 
endothelial dysfunction, vasoconstriction, and apoptosis. New drugs that target the harmful 
effects of myoglobin have been recently developed, and some have been proven to be 
successful in animal models of acute renal failure secondary to rhabdomyolysis. This review 
aims to provide a comprehensive and updated overview of the pathological mechanisms of 
renal damage and describes new therapeutic approaches to this condition based on novel 
compounds that target key pathways involved in myoglobin-mediated kidney damage.
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IntroductionRhabdomyolysis is the breakdown of damaged skeletal muscle and subsequent release of its contents (i.e., myoglobin, sarcoplasmic proteins, and electrolytes) into the plasma [1]. 
These products may be filtered through the glomeruli, leading to acute kidney injury (AKI) via different mechanisms, such as intratubular obstruction secondary to protein precipitation, 
renal vasoconstriction, inflammation, and tubular damage associated with reactive oxygen species (ROS) production. These harmful effects are produced in response to renal 
accumulation of myoglobin and heme derivates. This review aims to provide a comprehensive 
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and updated overview of the complex mechanisms involved in rhabdomyolysis-associated 
renal damage, describing novel therapeutic approaches to this pathological condition.
Epidemiology
The global prevalence of rhabdomyolysis is not fully known and appears to be underestimated. No large epidemiologic studies or updated registers on rhabdomyolysis are 
available. However, American reports suggest a global prevalence of 26,000 cases per year 
[2, 3]. The incidence of AKI among patients suffering from rhabdomyolysis is not exactly 
known, owing to different definitions of kidney injury and the etiological and population heterogeneity reported in these studies. Recent publications indicate that rhabdomyolysis 
causes between 7% and 10% of AKI cases each year in the United States [4]. Thus, it is 
estimated that AKI appears in 4% to 33% of patients with rhabdomyolysis [2].
Prognosis
Global rhabdomyolysis mortality is estimated between 2 and 46%, depending of the type of cause, early treatment administration and the presence of comorbid conditions and 
complications [5]. Most patients recover renal function in a few months [6], however even 
apparently resolved, AKI due to rhabdomyolysis promotes structural alterations, such as 
fibrosis and glomerulosclerosis, thus resulting in increased risk of chronic kidney disease, 
as previously observed in other AKI circumstances [7, 8]. These long-term adverse effects may be related not only to increased extracellular matrix production by renal cells, but 
also to a profibrotic role of infiltrating macrophages. Thus, macrophage depletion reduced 
fibrosis and improved rat survival in experimental rhabdomyolysis [8]. Nevertheless, studies 
analyzing long-term renal function outcome for rhabdomyolysis in  humans are lacking.
Molecular mechanisms in rhabdomyolysis
Massive muscular destruction can be due to various causes. It can result from direct 
muscle trauma (endogenous or exogenous) or muscle injury secondary to excessive muscle exertion, intrinsic metabolic alterations of muscle cells, or the toxic effects of chemical, physical, or biological agents (Figure 1) [1, 5]. Regardless of its cause, rhabdomyolysis 
produces multiple adverse effects on the kidney, such as oxidative stress, inflammation, 
apoptosis, vasoconstriction, and tubular obstruction (Figure 2).
Oxidative stress
During rhabdomyolysis, massive amounts of myoglobin are released from muscle cells 
and filtered by the glomerular filtration barrier [9]. Once filtered, myoglobin is endocytosed 
by tubular cells through the megalin-cubilin receptors [10]. Inside tubular cells, ferrous (Fe 2+) myoglobin is oxidized to a ferric (Fe 3+) form, leading to the formation of a hydroxyl 
radical, the most reactive of the ROS. In order to be stable, ferric myoglobin is transformed to ferryl (Fe 4+) myoglobin by redox cycling, yielding radical species. These radical species 
promote lipid peroxidation of membrane fatty acids [11, 12] and induce malondialdehyde 
synthesis, which mediates alterations of proteins and DNA [13, 14]. Lipid peroxidation of 
fatty acids results in the production of F2-isoprostanes, as observed in the urine of affected 
patients [15]. F2-isoprostanes are potent vasoconstrictors and promote the expression 
of intercellular adhesion factors such as VCAM-1 (vascular cell adhesion molecule-1) or 
intercellular adhesion molecule-1 (ICAM-1) as well as pro-inflammatory cytokines (MCP-
1), which promotes macrophage recruitment [8, 16, 17].In addition, the highly reactive 
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Fig. 1. Principal causes of rhabdomyolysis. 
Fig. 2. Molecular mechanisms in rhabdomyolysis. NF-kβ, Nuclear factor kappa B; RAAS, renin angiotensin 
aldosterone system; TGF-β, transforming growth factor-beta.
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ferrylmyoglobin, which is found in the urine of patients with rhabdomyolysis [18], acts as 
a potent nitric oxide scavenger, contributing to vasoconstriction, endothelial dysfunction, 
and platelet aggregation [11]. It is important to note that oxidation of myoglobin is a pH-
dependent process. Alkaline media tend to stabilize the ferryl species, making myoglobin 
less reactive [4].
Inflammation
Rhabdomyolysis-damaged muscle cells release immunostimulatory molecules, such 
as ligand high mobility group box proteins-1 (HMGB1), DNA, microRNAs and uric acid. 
These molecules reach kidney tissue, where they activate recently infiltrated dendritic cells, 
T-lymphocytes, and macrophages through the activation of complement cascade, Toll-like 
receptors (TLRs), and nuclear factor kappa beta (NF-κβ). Activation of these inflammatory 
cells promotes the production of pro-inflammatory cytokines, such as transforming 
growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF-α), thus resulting in the 
maintenance of a pro-inflammatory status [17, 19-21].
Myoglobin-derived heme also promotes pro-inflammatory effects on endothelial and tubular epithelial cells. Thus, cultured endothelial cells exposed to heme show an 
enhanced expression of the adhesion molecules ICAM-1 and VCAM-1 as well as E-selectin, 
thus leading to endothelial dysfunction [22]. Additionally, heme up-regulates α-chemokine 
and interleukin-8 (IL-8) gene expression and activates neutrophil protein kinase C [23]. 
In  response to heme, endothelial and tubular renal cells also release pro-inflammatory 
mediators, resulting in a positive feedback that perpetuates inflammatory response. As 
a result, infiltrated macrophages produce multiple cytokines such as TNF-α, IL-1β, and 
interferon-γ. Indeed, the number of infiltrated macrophage and pro-inflammatory cytokine 
levels has been positively correlated with loss of renal function and histologic injury in vivo 
[24]. It is well known that sterile inflammation triggered by tissue injury can be mediated 
through multiprotein complexes called the inflammasomes. In a recent article, it was 
reported that NLRP3 inflammasomes contributes to inflammation and tissue injury during 
the early phase of rhabdomyolysis-AKI [25]. In this pro-inflammatory scenario, renal cells may undergo dedifferentiation, acquiring the ability to proliferate, migrate, and produce 
extracellular matrix and pro-fibrotic mediators involved in glomerulosclerosis [7].
ApoptosisOne of the main regulators of ROS production and cell death is the mitochondria. 
In rhabdomyolysis, lipid peroxidation induces distortion of mitochondrial membrane 
permeability, resulting in a drop in cellular respiratory control, with amplification of ROS 
production, cytochrome C release, activation of caspases 1 and 3, and tubular-cell apoptosis 
[26, 27]. NLPR3 inflammasomes might also have a role in apoptosis because of its capability 
to activate caspase-1 pathway [25]. Inhibition of caspase 1 and 3 resulted in amelioration 
of renal damage in an experimental animal model of rhabdomyolysis [28]. The activation of 
c-JunN-terminal kinase (JNK) p38, the extracellular signal regulated kinase (ERK) pathways 
are involved in apoptosis control [29]. Either ERK or JNK is activated in rodent models of 
myoglobinuric AKI [30].
Vasoconstriction
A number of studies show that renal vasoconstriction associated with rhabdomyolysis is 
related to activation of the renin angiotensine aldosterone system (RAAS), which is induced 
by volume depletion secondary to fluid sequestration within damaged muscle. Another factor 
contributing to vasconstriction is the imbalance between vasocontrictors and vasodilator 
products that regulate renal blood flow. These factors are altered because of endothelial 
dysfunction [31],decreased oxide nitric bioavailability, and increased myoglobin-mediated 
F2-isoprostane production, having a potent vasoconstrictor effect [4, 11].
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Intratubular obstruction
In the tubular lumen, myoglobin may precipitate in combination with the Tamm-Horsfall 
protein, forming tubular casts, especially in presence of acid pH. This process is promoted by 
volume depletion, resulting in concentrated urine [1]. However, some authors indicate that 
tubular obstruction is merely the result of tubular-cell precipitation with myoglobin, and 
consequently does not need specific interventions other than preventing cellular death [11].
Molecular mechanisms involved in protection against rhabdomyolysis-induced 
renal damage
The main protective mechanism against myoglobin toxicity is mediated by heme-
oxygenase (HO), an antioxidant enzyme involved in heme degradation. HO-1 is the inducible 
isoform of HO, which is activated in the presence of several agents, including IL-6, IL-10, 
TNF-α, and ROS [32]. HO-1 knockout mice are more sensitive to rhabdomyolysis-associated 
AKI, showing increased creatinine and lactate dehydrogenase (LDH) plasma levels as well 
as elevated mortality [33]. The enzymatic degradation of heme by HO-1 produces carbon 
monoxide (CO), free iron, and biliverdin. CO is a potent ROS scavenger and inhibits the 
expression of pro-inflammatory cytokines such as TNF-α and IL-1β while promoting the 
expression of the anti-inflammatory cytokine IL-10 [34]. When released from heme, iron 
is incorporated into ferritin, decreasing free iron levels and protecting cells from oxidative 
stress. Ferritin also has anti-apoptotic effects. HO-1 promotes ferritin synthesis [35]. Finally, 
biliverdin is transformed into bilirubin by biliverdinreductase. Biliverdin promotes an anti-
inflammatory response in macrophages [36].Moreover, biliverdin and bilirubin are potent 
ROS scavengers [17].
Renal damage biomarkers in rhabdomyolysis
Classic biomarkers
Plasma detection of muscle-derived components has been used effectively for diagnosis 
of rhabdomyolysis. Hyperphosphatemia induces both phosphate and calcium deposition 
in the muscle, leading to initial hypocalcemia [36]. Calcium is later released during muscle 
necrosis. Additionally, increased hyperuricemia, carbonic anhydrase III and other proteases, 
such as LDH and aspartate aminotrasferase (AST), are observed. Increased urinary excretion 
of creatinine, uric acid, and glucose is also present due to the associated tubular damage [37].
New biomarkers
New early predictors of AKI in both blood and urine have been described in 
rhabdomyolysis. These biomarkers allow an earlier diagnosis as they provide indication of 
the development of incipient mechanisms before loss of renal function. Elevation of these 
biomarkers may be useful for early treatment administration and effective patient follow-
up. NGAL (neutrophil gelatinase-associated lipocalin) is the most widely investigated 
biomarker in rhabdomyolysis [38]. In the presence of toxic or ischemic injury, its production 
and liberation increase quickly, becoming detectable in urine and blood as a sensitive and 
specific renal-injury biomarker [39]. Moreover, NGAL levels have been positively correlated 
with mortality [40].
KIM-1 is an early biomarker of tubular damage. KIM-1 expression is increased in humans 
suffering from AKI secondary to renal ischemia due to cardiac surgery. An association 
between KIM-1 elevation and both the extrarrenal depuration treatment requirements 
and mortality has been reported. However, these biomarkers have no application in clinical 
practice to date [41]
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Global therapeutic approach
Classic strategies
Intensive fluid resuscitation has been effectively used in rhabdomyolysis treatment. 
It is important to monitor diuresis rate and stop fluid infusion if signals of overhydration 
appear [5, 42]. Alkalinization with intravenous bicarbonate has also shown benefits in animal models by reducing cast formation by inhibiting precipitation of myoglobin with 
Tamm-Horsfall protein. Moreover, myoglobin oxidation is inhibited by alkalinization [15, 
43]. However, human studies validating the employment of bicarbonate in patients suffering from rhabdomyolysis are scarce. These studies are either hindered by a small simple size or employ different combinations of alkaline agents, making it impossible to fully establish the 
efficacy of alkalization. In addition, alkalization is not always harmless, since it can worsen hypocalcemia in the early stages of rhabdomyolysis, stimulating the precipitation of calcium 
and phosphorus in muscle tissue [44, 45].
Once euvolemia is restored, the use of diuretics is sometimes necessary, although 
their use is controversial. Mannitol is an osmotic diuretic that increases urinary flow, 
prevents myoglobin precipitation, and has ROS scavenging capacity [2, 46]. In mice with 
rhabdomyolysis, it has been observed that mannitol administration along with bicarbonate 
reduces oxidative stress and restores urinary flow to a greater extent than fluid resuscitation 
alone [47]. However, no randomized clinical trials are available in humans, although some 
retrospective reports showed no beneficial effect on either renal function or mortality [44]. 
Similarly, the use of the loop diuretics furosemide and torasemide has not been specifically 
recommended in rhabdomyolysis, being used as in other AKI circumstances [48].
In cases of rhabdomyolysis, fluid and electrolyte disturbances should always be detected in early stages and carefully treated. The presence of refractory hypercalcemia, metabolic acidosis, or refractory oligoanuria calls for the use of renal replacement therapy either by 
conventional hemodialysis or continuous renal replacement therapy (CRRT). Conventional hemodialysis does not eliminate myoglobin because of its high molecular weight. Therefore, 
although hemodialysis resolves the effects of renal dysfunction such as uremia and fluid 
overload, it does not prevent the toxic effects of myoblobinon kidneys. Nevertheless, 
some authors have reported effective removal of myoglobin when high-flux dialyzers are 
employed for hemodialysis in patients with myoglobinuric AKI [49, 50]. Similarly, high cut-
off membranes with larger pore sizes have been shown to be effective in removing myoglobin 
[51]. A randomized open clinical trial comparing the new high cut-off dyalizerSepte X® vs. 
conventional high-flux dialysis treatment to eliminate plasma myoglobin is currently under 
way (NCT01467180). CRRT is also capable of eliminating myoglobin, especially when high 
convective volumes are employed [52]. A study in dogs has revealed that CRRT-mediated myoglobin reduction protects kidney tissue by reducing mitochondrial dysfunction, and 
consequently cellular apoptosis [53]. Plasma exchanges with plasmapheresis have also 
produced good results in cases of rhabdomyolysis [54, 55].
New therapeutic strategies
Iron chelators and antioxidant treatment. Desferrioxamine is an iron chelator that 
decreases rhabdomyolysis-derived kidney injury in rats [56] and inhibits lipid peroxidation by 
reducing myoglobin to its ferrous form [57]. However, desferroxamine has direct nephrotoxic 
effects, which are enhanced by its hydrophilic nature. This limitation can be resolved by 
conjugating desferrioxamine to adamantyl derivatives, obtaining desferrioxamine B-N-(3-
hydroxyadamant-1-yl), which is lipophilic and less cytotoxic than original desferrioxamine 
and preserves the anti-inflammatory and antioxidant capacity, as demonstrated in animal 
models [58]. The oral alternatives to desferrioxamine are α-hidroxipyridines, such as 
deferiprone, which has been effectively tested in large clinical trials and is currently available 
for clinical use in situations of ferrous overload by repeated blood transfusions [59]. However, 
there are no studies testing its efficacy to prevent or treat AKI in rhabdomyolysis.
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Antioxidant treatment. Acetaminophen is a peroxidase substrate that inhibits lipid 
peroxidation by reducing ferryl myoglobin to the ferric state [60]. In animal models of 
rhabdomyolysis, treatment with this agent reduced urinary levels of F2-isoprostanes and ferrylmyoglobin, with consequent reduction in lipid peroxidation, kidney damage, and 
loss of proximal tubular cells [61].The effects of acetaminophen did not depend on muscle damage reduction because myoglobin deposits in treated kidneys were present to the same 
extent as in untreated kidneys. Interestingly, this effect was observed when acetaminophen 
was given both before and after inducing the injury, indicating that this drug can be used not only for prophylaxis but also for treatment [11].
N-acetylcysteine (NAC) is a source of glutathione and sulfhydryl (GSH) groups in cells and 
has ROS scavenger capacity [11]. The protective effects of NAC have been proven in models of 
cisplatin-induced nephrotoxicity [62], ischemia-reperfusion injury [63], and chronic kidney 
disease [64]. NAC also reduced renal damage in a rat model of rhabdomyolysis, preventing 
celular apoptosis via inhibition of ERK and JNK signaling pathways and oxidative stress [65]. 
A randomized double-blinded trial comparing the efficacy of CRRT and N-acetylcysteine in 
preventing renal failure in rhabdomyolysis has recently been completed, although the results 
have not yet been published (NCT00391911).
Vitamin E (α-tocopherol) is the major lipophilic antioxidant present in cellular 
membranes, protecting them against lipid peroxidation [66]. For this reason, it has been 
suggested as a possible protective molecule to prevent myoglobin tubular toxicity [67]. 
However, its liposolubility implies a low capacity to prevent the initial myoglobin oxidation 
in the urine [11]. Vitamin C (ascorbic acid) also has antioxidant effects but has the advantage of being water soluble, and is probably capable of blocking the oxidation of myoglobin in 
the urine [11]. Polyphenols are lipid-soluble antioxidants that have synergic effects with 
vitamin C. In a murine model of rhabdomyolysis, rats were treated either with 3,3’,5,5’-tetra-
tert-butyl-biphenyl-4,4’-diol or with vitamin C [68]. The authors of the study observed 
that both compounds protected the kidney from oxidative damage and inflammation by 
inhibiting ERK-mediated MCP-1 production. Nevertheless, only animals treated with vitamin 
C presented some clinical benefit (reduction in proteinuria and hyperuricemia). This result 
suggests that vitamin C may have some additional effect besides its antioxidant role. 
Daily administration of flavonoids from red wine reduced blood CPK as well as cathalase, glutathione peroxidase, and superoxide dismutase expression in a rat model of 
rhabdomyolysis [69].
The potential utility of L-carnitine in myoglobinuric AKI has also been demonstrated 
[70]. Thus, administration of L-carnitine significantly decreased CPK, creatinine, and urea 
levels as well as necrosis, iron accumulation, and cast formation as compared to the control group.
Anti-inflammatory treatments. Liposome-encapsulated clodronate (LEC) administration 
is a well-known method for depleting mononuclear phagocytes in mice. Phagocytes 
incorporate LEC and undergo apoptosis [71]. Treatment with LEC in a mouse model of 
rhabdomyolysis led to depletion of infiltrating macrophages, causing preservation of 
renal function and decreased NF-κβ mediated inflammatory response and production 
of profibrotic mediators such as TGF-β [24, 72]. Moreover, LEC treatment reduced the 
expression of extracellular matrix molecules such as MMP-2 and MMP-9 in both infiltrating 
inflammatory and tubular cells. This effect was not attributable to muscular protection 
because no differences in CPK were observed between groups [24].
Suramine is a polysulfonated naphtylurea used in humans to treat trypanosomiasis. It 
has been demonstrated that this compound accelerates recovery from AKI due to ischemia/
reperfusion injury, obstructive nephropathies, and renal fibrosis in mice [73]. In one study, suramine was employed in rats with rhabdomyolysis, resulting in amelioration of 
kidney function and histology [74]. In fact, treated animals showed decreased KIM-1 renal 
expression, inhibition of apoptosis by reduction of caspase-3 activation, and decreased 
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inflammation, as denoted by reduced NF-κβ activation and consequent reduction in IL-1β, 
ICAM-1, and leukocyte infiltration.
Pentoxifylline is a substituted methylxanthine with protective properties caused by 
adenosine receptor antagonism. Pentoxifylline inhibits proliferation of rat mesangial cells 
and mRNA collagen expression [75] as well as inhibiting myofibroblasts differentiation 
[76]. Treatment with pentoxifylline in a rat model of myoglobinuric AKI reduced interstitial 
mononuclear cell infiltration [77].
Mesenchymal stem-cell (MSC) administration has shown protective effects against 
rhabdomyolysis-induced kidney damage in mice [78]. Despite the fact that some authors 
have observed that MSC migration and trans-differentiation into functional parenchymal 
cells can exert reparative actions, its beneficial effects are mainly ascribed to their paracrine 
actions. It has been suggested that MSC presence promotes intra-renal accumulation of 
protective M2 macrophages, with increased production of the anti-inflamatory IL-10 and 
decrease of IL-6 and TNF-α [79]. In humans, stem-cell based therapy has been tried for 
stroke, with apparently good results, however different recent meta-analysis report that 
further investigation is needed to test clinical efficacy and safety [80, 81].
Regarding elimination techniques, an ongoing clinical trial is evaluating the efficacy 
of a new extracorporeal blood filter, Cytosorb®, in rhabdomyolysis (NCT02111018). This cartridge is a polymer with immunomodulatory actions by adsorbing cytokines, such as 
TNF-alpha, IL-1beta, IL-6 and IL-8, as blood pass through the device [82]. Some studies have 
shown its beneficial effects on the inflammatory response and survival rate in septic rats 
[83]. Moreover, in critically ill patients, treatment with cytokine adsorbing columns resulted 
effective on hemodynamics and organ failure [84]. Nevertheless, it is not well understood 
whether this filter can also eliminate protective anti-inflammatory cytokines, therefore 
reducing the natural anti-inflammatory response [85]. 
Vasoconstriction inhibition
Vasoconstriction is a partial consequence of nitric oxide scavenging by myoglobin; 
therefore, agents capable of increasing nitric oxide have been tested to prevent 
rhabdomyolysis-induced damage. L-arginine (nitric oxide precursor) and moldosine 
(nitric oxide donor) exhibited nefroprotective effects in animal models of rhabdomyolysis-
associated AKI [86]. F2-isoprostanes exert their vasoconstrictor effect through tromboxane-
receptor activation. This is why tromboxane receptor blockers could play a protective role in 
rhabdomyolysis, as has been demonstrated recently [87]. It has been confirmed that there 
are erythropoietin receptors (EPO-R) on tubular cells. Recombinant erythropoietin (rhEPO) 
can protect these cells from ischemia-reperfusion and cisplatin toxicity [88]. Moreover, in 
animal models of rhabdomyolysis, it has been observed that treatment with rhEPO leads to a 
reduction in renal damage and amelioration of renal function by decreasing NF-κβ activation 
[89]. As far as we know, no studies in humans have been developed to test the efficacy of 
rhEPO in rhabdomyolysis. However, given the increased risk of hypertension, cancer and 
thromboembolic events associated to this agent, result necessary to take care when trying to 
validate its clinical use for an indication different from the already admitted in humans [90].
Conclusion
A variety of mechanisms lead to kidney damage in rhabdomyolysis. One of the most 
important is kidney hypoperfusion secondary to fluid sequestration within damaged muscle 
and to vasoconstriction due to RAAS activation. Hypoperfusion is also a result of intratubular 
myoglobin presence causing overproduction of vasoconstrictive agents and vasodilators 
reduction. Additionally, intratubular myoglobin induces oxidative stress, inflammation, and 
tubular obstruction. Classical treatments including fluid infusion and alkalization restore 
renal function by increasing volemia and inhibiting tubular obstruction; however, their use 
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is controversial and human studies validating their use are scarce. The actual understanding 
of pathophysiological mechanisms involved in rhabdomyolysis is associated to experimental studies, and there is no current clinical application of such knowledge. New antioxidant 
and anti-inflammatory therapies have shown efficacy in animal models, neutralizing the 
deleterious effect of myoglobin. Therefore, controlled clinical trials are needed to evaluate 
the potential benefit of these approaches in the prevention or treatment of AKI secondary 
to rhabdomyolysis. Prospective studies may be required to better define long-term adverse 
effects of rhabdomyolysis, identify prognostic factors and define a management strategy. 
Until new specific treatments are available, classical supportive care strategies should be recommended. 
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